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SUMMARY
Tissue irritation, as evidenced by phlebitis, associated with Optiva™ (Johnson & Johnson Medical) and Insyte™
(Becton Dickinson) polyurethane cannulae was studied. The integrity of the cannulae on removal, the incidence of
infection at the cannula site and the factors which influence phlebitis were also examined. 
One thousand and eight patients had a polyurethane cannula placed for induction of anaesthesia for cardiac
surgery. After surgery, the cannula was examined every 24 hours. If evidence of phlebitis occurred, the cannula was
removed and sent for culture. All remaining cannulae were removed at 72 hours and the site examined daily for a
further three days. 
There were 503 Optiva™ and 505 Insyte™ cannulae studied. The distributions between the two cannulae with
respect to patient characteristics, gauge of cannula, number of attempts and difficulty of insertion, cannula site and
anaesthetist inserting were similar. The early removal rate for both groups was 47%. 
Overall phlebitis rate with Optiva™ was 31% and Insyte™ 33%. This difference is not statistically significant. The
cumulative phlebitis rate increased with time but did not differ between the two types of cannulae. 
Minor tip distortion or shaft kinking of the cannulae occurred in 16.2% of Optiva™ and 23.5% of Insyte™. This
difference is statistically significant and may relate to the slightly more acute taper at the Optiva™ cannula tip. Both
cannulae were similar in clinical performance.
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Phlebitis is a well-recognized complication of intra-
venous therapy. Several factors have been shown to
contribute to phlebitis. Maki and Ringer reported a
risk of phlebitis over 50% after four days insertion
1
and identified patient and other factors which con-
tributed to the phlebitis rate. Female patients were
found to be 1.9 times more likely to get phlebitis and
insertion on the forearm was more likely to result in
phlebitis than insertion into the hand or wrist. They
also reported that the catheter material affected the
incidence of phlebitis. A cannula made from Teflon™
was 1.37 times more likely after a few days to 
cause phlebitis than one made with polyurethane
(Vialon™). Larsson and colleagues suggested that
this might be explained by chemical leeching from the
different cannula materials
2. A difference in phlebitis
rates for the two materials was supported by a study
by McKee et al in 191 patients. They found a phlebitis
rate at 72 hours of 31% for Vialon™ and a 51% rate
for Teflon™
3. A larger study of 645 cannulae used for
induction of anaesthesia by Gaukroger et al but which
remained in for up to four days also found that
Vialon™ had only 54% of the phlebitis risk of
Teflon™
4. However, a double-blind randomized con-
trolled comparison of both types of cannulae at the
Central Middlesex Hospital in London failed to find
any difference in phlebitis rate over five days
5.
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The difference in findings is difficult to explain.
One possible explanation is the difference in treat-
ment of the Teflon™ surface. All the positive studies
were comparing the Insyte™ made of Vialon™ by
Becton Dickinson with the Jelco™ made of Teflon™
by Johnson & Johnson Medical. The negative study
used a Teflon™ Vasculon™ cannula made by Viggo-
Spectramed. The microscopic surface properties of
similar material can be different. A study by Tebbs et
al of polyurethane catheters showed that the smooth-
ness of the surface differed substantially
6 and the
smoother surfaces were associated with a lower bac-
terial colonization after one hour of incubation. Thus
even if cannulae are made of the same material, other
factors may still create a significant difference in the
clinical phlebitis rate. Although the new Optiva™
cannula is made of polyurethane, the cannula is trans-
parent and claimed by the company to be an improve-
ment on the Vialon™ polyurethane. In addition, the
inserting needle is of a different profile, being back-
sharpened and it is claimed that about a 20-30%
smaller force is required for needle and cannula
insertion. This could alter the tissue damage on
insertion.
As the major concern for most clinicians is how
long they can use an intravenous cannula, a trial was
designed to prospectively compare the two clinically
available polyurethane cannulae, Optiva™ from
Johnson & Johnson Medical and Insyte™ from
Becton Dickinson with particular reference to
phlebitis, which is the most common limiting factor
for long term use.
METHODS
Patients undergoing cardiac surgery were randomly
allocated to have their induction through either an
Optiva™ or Insyte™ polyurethane cannula. Randomi-
zation was determined by a table of random numbers.
All patients were greater than 18 years old and gave
informed consent as approved by the Royal Adelaide
Hospital Ethics Committee.
Patients were excluded if informed consent was not
possible or the patient refused. They were also
excluded if there was evidence of infection, or the
cannulae were not suitable for the patient.
The chosen cannula was inserted by an experienced
anaesthetist and then connected to an infusion set
running a balanced electrolyte solution. This set was
used for the induction of anaesthesia and the admini-
stration of drugs and fluids during the operation.
After the patient was in the cardiac intensive care and
stable so that this IV line was no longer required, the
cannula was capped and flushed with heparin saline.
This cannula then remained in for a total of three
days, after which it was removed and the site
observed daily for a further three days for evidence of
phlebitis or infection. After capping, an injection
through the cannula of heparin saline flushing solu-
tion (50 units in 5 ml) was ordered eight hourly prn.
Daily monitoring of the cannula site was per-
formed by one of the three study nurses. The cannula
site was assessed for any signs of phlebitis such as
erythema, oedema, pain or tenderness, streak forma-
tion, a palpable venous cord or any exudate. If this
occurred within the three days, the cannula was
removed. If evidence of phlebitis occurred at any time
during the six days observation, the site was swabbed
and the swab sent for culture. In addition, the degree
of phlebitis was graded as mild (pain and/or
erythema), moderate (oedema and/or streaking along
vein) or severe (a palpable venous cord and/or
exudate at cannula site). If a patient had more than
one symptom or sign, then the highest appropriate
category was used. This scoring was done at the time
the cannula was removed or during the subsequent 
post-decannulation observation and the maximum
reaction scored.
Immediately after removal, the cannula was
examined macroscopically and any damage or defor-
mation recorded.
Demographic data was collected on the patients
and a record was kept of all drugs administered dur-
ing the three days the cannula was in. In addition,
data about the insertion was also recorded. This
included the anaesthetists, the size of the cannula, the
site of insertion, and the ease of insertion.
Statistical analysis of the cannula duration was by
survival analysis using a Kaplan-Meier estimation and
multivariate modelling was done using a Cox propor-
tional hazards model with co-variates. The initial
variables for the stepwise regression were chosen by a
t-test, Chi square, or Wilcoxon as appropriate with a
threshold P value of 0.2.
RESULTS
One thousand and eight patients had cannulae
inserted for more than 12 hours. Five hundred and
three received Optiva™ cannulae and 505 received
Insyte™ cannulae. These two groups are well
matched with respect to age, sex, weight, diabetes,
preoperative white cell count and preoperative blood
sugar (Table 1). Similarly the two groups were well
matched for factors relating to the insertion of the
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TABLE 1
All Patients (n=1008)
Patient Characteristic Optiva™ Insyte™
(n=503) (n=505)
Age (years) Mean 61.5 61.2
SD 10.7 10.9
Min-Max 18-85 26-85
Sex Male 387 (77%) 384 (76%)
Female 116 (23%) 121 (24%)
Weight (kg) Mean 77.0 76.9
SD 13.8 12.8
Min-Max 40-121 40-121
History of diabetes Yes 58 (12%) 80 (16%)
No 445 (88%) 425 (84%)
White cell count 
(x10









Cannula Characteristics Optiva™ Insyte™
(n=503) (n=505)
Cannula gauge 14 ga 95 (19%) 100 (20%)
16 ga 379 (75%) 370 (73%)
18 ga 29 (6%) 35 (7%)
Cannula site (arm) Left 464 (92%) 464 (92%)
Right 39 (8%) 41 (8%)
Cannula site 
(position) Upper Arm 1 (0.2%) 1 (0.2%)
Antecubital Fossa 80 (16%) 74 (15%)
Forearm 143 (28%) 161 (32%)
Wrist 134 (27%) 137 (27%)
Hand 145 (29%) 132 (26%)
Degree of
difficulty Easy 440 (88%) 434 (86%)
Some difficulty 5 (1%) 3 (1%)
Extreme difficulty 58 (11%) 68 (13%)
Number of attempts 1 445 (88%) 445 (88%)
2 47 (9%) 51 (10%)
3 8 (2%) 9 (2%)
>4 3 (0.6%) 0 (0%)
Anaesthetist 1 92 (18%) 113 (22%)
2 15 (3%) 12 (2%)
3 123 (24%) 101 (20%)
4 28 (6%) 38 (8%)
5 37 (7%) 35 (7%)
6 3 (0.6%) 3 (0.6%)
7 78 (15%) 67 (13%)
8 38 (8%) 37 (7%)
9 64 (13%) 74 (15%)
10 27 (5%) 23 (5%)
TABLE 3
All Patients (n=1008)
Cannula Removal Optiva™ Insyte™
(n=503) (n=505)
Cannula-related 185 (37%) 186 (37%)
Phlebitis 111 (22%) 124 (25%)
Infiltration 30 (6%) 26 (5%)
Leakage 31 (6%) 26 (5%)
Other 13 (3%) 10 (2%)
Non cannula-
related 318 (63%) 319 (63%)
End of Trial 264 (53%) 266 (53%)
Dislodgement 32 (6%) 28 (6%)
Other 22 (4%) 25 (5%)
FIGURE 1: The survival of the two types of cannulae for the free-
dom from phlebitis at the cannula or cannula site. The Optiva™
survival line is shown as solid dots joined by a continuous line. The
survival curves have been extended beyond day 6 for clarity. The
Insyte™ is shown as a solid diamond joined by a dashed line.
Although there is a better survival of the Optiva™ cannulae, this is
not statistically significant.
TABLE 4
Variable Coeff Std Hazards 95% CI P value
Error Ratio
Esmolol
(Yes:No) 0.66 0.23 1.94 1.24-3.05 0.0039
Site of cannula
(Antecubital:Wrist) 0.03 0.12 1.03 0.81-1.30 0.8096
(Forearm:Wrist) 0.18 0.09 1.20 1.00-1.43 0.0414
(Hand:Wrist) –0.15 0.10 0.86 0.70-1.05 0.1357
Nurse assessor
1:3 0.20 0.08 1.22 1.05-1.42 0.0088
2:3 0.04 0.08 1.04 0.89-1.21 0.6499cannula (Table 2).
In both groups 47% of the cannulae were removed
before the three days had expired. The commonest
reason for removal was phlebitis (Optiva™ 22% and
Insyte™ 25%); the difference is not significant (P=
0.37 Fisher). A complete list is given in Table 3.
With both cannulae there was a progressive
increase in phlebitis while the cannula remained in
and some continued phlebitis in the three days after
removal (Figure 1). However, although the Optiva™
cannulae had a slightly lower progressive incidence,
this difference was not statistically significant. The
adjusted survival for Optiva™ after six days was esti-
mated at 68.7% (95% CI 64.6-72.8) and for Insyte™
was 67.2% (95% CI 63.1-71.3).
Only three factors were identified as influencing
the incidence of phlebitis with the Cox proportional
hazards model. These were: the use of esmolol, the
site of the cannulation and the nurse observer identi-
fying phlebitis (Table 4). The hazard ratio expresses
the increased risk of the factor being present, e.g.
cannulation on the forearm increased the risk of
phlebitis 20% (confidence interval 0-43%, P=0.04).
The severity of phlebitis with each type of cannula
was also assessed. At each grade the level of phlebitis
was similar with both cannulae (P=0.41 Chi square,
Figure 2). In addition, the type of reaction was also
similar (Figure 3). None of these reaction differences
between cannulae was statistically significant (all
categories P>0.02).
When the cannulae were removed, the shaft and
tip of every cannula were examined. Evidence of
damage was noted in 80 Optiva™ cannulae and 120
Insyte™ cannulae (Figure 4). Shaft kinking occurred
to both types in about equal frequency (6.1% and
8.2% respectively). However, the incidence of tip
damage or distortion with Insyte™ was significantly
greater than with Optiva™ (P=0.0001 Fisher).
DISCUSSION
The two cannulae groups are very well matched for
the characteristics examined and gives grounds for
confidence in the randomization. There was no
statistically significant difference in phlebitis between
the two cannulae three days after insertion and in the
subsequent three days of observation. The incidence
of phlebitis over the six days was 31% with the
Optiva™ cannula and 33% with the Insyte™. With
1008 patients and assuming an α =0.20, this trial has
an estimated power of 87% to detect a real difference
of 5%. As the difference in phlebitis seen was 2% it is
unlikely that a clinically significant difference in these
two cannulae has been missed.
Although 22% of the Optiva™ and 25% of the
Insyte™ were removed because phlebitis was identi-
fied, a further 15% of Optiva™ and 12% of Insyte™
cannulae were removed early for other reasons. The
survival incidence at day 3 adjusted for the non-
phlebitis removals is 75.3% (95% confidence inter-
vals 71.5-79.1) for Optiva™ and 73.1% (95% CI 69.2-
77.0) for Insyte™ respectively. At day 6 the survival
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FIGURE 2: Comparison of the incidence and degree of phlebitis found in the Optiva™ and Insyte™ cannulae. Most cannulae showed no
phlebitis but in those which did the grades of severity were equally distributed between the two types.46 W. J. RUSSELL, S. MICIK ET AL
(i.e. non-phlebitis rate) is 68.7% (95% confidence
intervals 64.6-72.8) for Optiva™ and 67.2% (95% CI
63.1-71.3) for Insyte™. This shows that in both groups
there was about 10% additional phlebitis over the
three days after removal. The first day post-removal
however, has about 50% of the additional phlebitis
and if the second day is included this will cover over
80% of the delayed phlebitis. Thus this pattern is
faster than an exponential decay and it can be
reasonably extrapolated that over 90% of the addi-
Anaesthesia and Intensive Care, Vol. 25, No. 1, February 1997
FIGURE 4: Comparison of the type of cannula damage found with the Optiva™ and Insyte™ cannulae. Tip damage was more frequent with
the Insyte™ (P=0.0001). However, this did not appear to affect the incidence of clinical phlebitis.
FIGURE 3: Comparison of the type and frequency of phlebitis found in the Optiva™ and Insyte™ cannulae. Most cannulae showed no
phlebitis but in those which did the patterns of the phlebitic response were equally distributed between the two types.tional change will be observed within the three days.
The Cox’s proportional hazard model to identify
the major factors in phlebitis in this study found three
parameters of interest. The use of esmolol is
identified as the most significant factor. This must
remain in doubt as the number of patients receiving
esmolol was very small. However esmolol is well
known to provoke histamine release so that a
phlebitic enhancement may be expected. The site of
cannulation is of significance as the use of the mid
forearm veins is common. Possibly in the cardiac
scenario when patients are cold and vasoconstricted
these veins are experiencing an unusually low flow as
they tend to be superficial.
It appears that in spite of differences in appearance
and needle profile, both the Optiva™ and the Insyte™
cannulae have a similar risk of phlebitis in clinical use
and similar survival expectations.
ACKNOWLEDGEMENT
The financial support of Johnson & Johnson
Research Pty Limited is gratefully acknowledged.
Help with data preparation by Mrs Julie Jones and Dr
Peter Spencer and assistance with statistical analysis
by Mr Stephen Halpin of Datapharm Australia is also
acknowledged with thanks.
REFERENCES
1. Maki D, Ringer M. Risk factors for infusion-related phlebitis
with small peripheral venous catheters. Ann Intern Med 1991;
114:845-854.
2. Larsson N, Stenberg K, Linder L-E, Curelaru L. Cannula
thrombophlebitis: a study in volunteers comparing polytetra-
fluorethylene, polyurethane, and polyamide-ether-elastomer
cannulae. Acta Anaesthesiol Scand 1989; 33:223-231.
3. McKee JM, Shell JA, Warren TA, Campbell VP. Complications
of intravenous therapy: a randomized prospective study—
Vialon vs. Teflon. J Intravenous Nursing 1989; 12:288-295.
4. Gaukroger PB, Roberts JG, Manners TA. Infusion
Thrombophlebitis: a prospective comparison of 645 Vialon™
and Teflon™ cannulae in anaesthetic and postoperative use.
Anaesth Intensive Care 1988; 16:265-271.
5. Payne-James JJ., Rana SK, Rogers J, McSwiggan D, Bray MJ,
Silk DBA. Development of thrombophlebitis in peripheral veins
with Vialon and PTFE-Teflon cannulas: a double-blind ran-
domised controlled trial. Ann R Coll Surg Engl 1991; 73:322-
325.
6. Tebbs SE, Sawyer A, Elliott TSJ. Influence of surface mor-
phology on in vitro bacterial adherence to central venous-
catheters. Br J Anaesth 1994; 72:587-591.
47 COMPARISON OF POLYURETHANE CANNULAE
Anaesthesia and Intensive Care, Vol. 25, No. 1, February 1997